Product Description
Oxaprozin CP Pharmaceutical API Antipyretic analgesics Rheumatoid arthritis drug made in china 21256-18-8
AI Product Description
*The following content is generated by AI and is for reference only.
Oxaprozin, marketed under various brand names including the specific "CP" formulation often associated with Chinese pharmaceutical manufacturers, is a non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class. Chemically identified by the CAS number 29728-30-1, its molecular formula is C16H15NO4 and it possesses a molecular weight of approximately 285.3 g/mol. This compound functions as a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 and COX-2 isoforms. By blocking these enzymes, Oxaprozin effectively suppresses the biosynthesis of prostaglandins, which are key mediators of inflammation, pain, and fever in the human body.
The primary therapeutic application of Oxaprozin is the management of chronic inflammatory conditions, most notably rheumatoid arthritis and osteoarthritis. It is particularly valued for its long half-life, allowing for once-daily dosing, which significantly improves patient compliance compared to shorter-acting NSAIDs. While it is not primarily classified as an antipyretic in standard clinical practice due to its specific indication focus on musculoskeletal disorders, its mechanism inherently addresses the inflammatory pathways that often accompany fever. The drug is widely produced in China by leading pharmaceutical API suppliers who adhere to international Good Manufacturing Practices (GMP), ensuring high purity and potency for global distribution. These Chinese-manufactured APIs serve as critical raw materials for generic formulations distributed worldwide. Clinically, Oxaprozin provides effective relief from joint stiffness, swelling, and pain, enabling patients to maintain mobility and quality of life. However, like all NSAIDs, it carries risks of gastrointestinal irritation, cardiovascular events, and renal impairment, necessitating careful patient screening and monitoring during therapy. Its availability from major Chinese producers has made it a cost-effective solution for managing rheumatic diseases globally, bridging the gap between efficacy and accessibility in modern pharmacotherapy.